◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › N › NVS

Novartis AG ADR (NVS) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · DATA UPDATED 2026-09-19

Novartis AG ADR (NVS) operates in the DRUG MANUFACTURERS - GENERAL industry and is headquartered in Basel, Switzerland with about 75,267 employees. Its market capitalization is roughly $267 billion. In the fiscal year ended 2025-12-31, NVS reported $54.8B in revenue and $14.1B in net income.

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.

Interactive charts & full statements → Open the NVS valuation workbench →

NVS Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$56.2B	$54.8B	$51.7B	$46.7B	$43.5B	$44.0B	$49.9B	$48.7B	$46.1B	$43.4B	$49.4B	$50.4B	$53.6B	$52.7B	$52.0B	$59.4B	$51.6B	$45.1B	$42.6B	$38.9B	$35.1B
Gross Profit	$41.9B	$41.1B	$38.9B	$34.2B	$31.9B	$32.2B	$34.8B	$34.3B	$31.6B	$29.8B	$31.9B	$33.0B	$36.3B	$36.1B	$36.1B	$40.4B	$37.1B	$32.9B	$31.1B	$27.9B	$25.7B
Gross Margin %	74.6%	75.0%	75.2%	73.3%	73.4%	73.3%	69.7%	70.4%	68.5%	68.6%	64.6%	65.5%	67.7%	68.5%	69.5%	68.0%	71.9%	73.0%	73.1%	71.7%	73.2%
Operating Income (EBIT)	$17.0B	$17.1B	$14.5B	$9.8B	$7.9B	$10.1B	$10.2B	$9.1B	$8.4B	$8.7B	$8.3B	$9.0B	$11.1B	$11.0B	$11.5B	$10.8B	$11.5B	$10.0B	$9.0B	$6.8B	$7.6B
Operating Margin %	30.3%	31.1%	28.1%	20.9%	18.3%	22.9%	20.3%	18.7%	18.2%	20.1%	16.7%	17.8%	20.7%	20.8%	22.1%	18.2%	22.4%	22.1%	21.1%	17.4%	21.8%
Net Income	$12.8B	$14.1B	$11.9B	$14.8B	$7.0B	$24.0B	$8.1B	$11.7B	$12.6B	$7.7B	$6.7B	$17.8B	$10.2B	$9.2B	$9.3B	$8.9B	$9.8B	$8.4B	$8.2B	$11.9B	$7.2B
Net Margin %	22.7%	25.6%	23.1%	31.8%	16.0%	54.6%	16.2%	24.1%	27.4%	17.8%	13.6%	35.3%	19.0%	17.4%	17.8%	15.1%	19.0%	18.6%	19.2%	30.7%	20.4%
EBITDA	—	$23.0B	$20.7B	$18.3B	$14.7B	$30.9B	$17.2B	$15.6B	$20.2B	$14.6B	$14.6B	$14.3B	$17.7B	$15.9B	$16.4B	$17.1B	$15.8B	$12.8B	$12.5B	$10.6B	$10.2B
Earnings Per Share (EPS)	$6.63	$7.19	$5.87	$7.10	$3.17	$10.63	$3.52	$5.06	$5.38	$3.25	$2.80	$7.29	$4.13	$3.70	$3.79	$3.70	$4.26	$3.69	$3.59	$5.13	$3.04
Shares Outstanding (M)	—	1,955M	2,035M	2,092M	2,197M	2,260M	2,296M	2,319M	2,344M	2,371M	2,400M	2,438M	2,470M	2,479M	2,445M	2,413M	2,301M	2,277M	2,284M	2,329M	2,360M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NVS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$15.0B	$13.5B	$13.3B	$14.4B	$14.8B	$13.6B	$13.6B	$13.2B	$12.9B
Gross Profit	$11.2B	$10.1B	$9.8B	$10.8B	$11.5B	$10.4B	$10.2B	$9.9B	$9.7B
Gross Margin %	75.2%	74.4%	73.4%	75.3%	77.6%	76.3%	75.5%	75.4%	75.3%
Operating Income (EBIT)	$4.8B	$4.2B	$3.5B	$4.5B	$4.9B	$4.7B	$3.5B	$3.6B	$4.0B
Operating Margin %	31.8%	31.3%	26.4%	31.4%	32.8%	34.2%	26.0%	27.5%	31.2%
Net Income	$3.3B	$3.2B	$2.4B	$3.9B	$4.0B	$3.6B	$2.8B	$3.2B	$3.2B
Net Margin %	21.8%	23.3%	18.1%	27.4%	27.2%	26.5%	20.8%	24.2%	25.2%
EBITDA	—	$5.4B	$5.1B	$5.8B	$6.1B	$5.8B	$5.2B	$5.6B	$5.2B
Earnings Per Share (EPS)	$1.71	$1.65	$1.25	$2.02	$2.06	$1.82	$1.41	$1.57	$1.59
Shares Outstanding (M)	—	1,916M	1,929M	1,940M	1,960M	1,979M	2,004M	2,027M	2,046M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NVS Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$18.4B	$19.2B	$17.6B	$14.5B	$14.2B	$15.1B	$13.7B	$13.6B	$14.3B	$12.6B	$11.5B	$11.9B	$13.9B	$13.2B	$14.2B	$14.3B	$14.1B	$12.2B	$9.8B	$9.2B	$8.7B
Capital Expenditures (CapEx)	$3.0B	$1.6B	$3.8B	$2.8B	$2.7B	$3.0B	$2.6B	$2.3B	$3.4B	$2.7B	$2.9B	$3.9B	$3.7B	$3.8B	$3.3B	$2.4B	$2.2B	$2.7B	$2.3B	$3.1B	$2.3B
Free Cash Flow (FCF)	$15.4B	$17.7B	$13.8B	$11.7B	$11.6B	$12.1B	$11.1B	$11.4B	$10.9B	$9.9B	$8.6B	$8.0B	$10.2B	$9.4B	$10.9B	$11.9B	$11.8B	$9.5B	$7.5B	$6.1B	$6.4B
FCF Margin %	27.4%	32.3%	26.7%	25.1%	26.6%	27.5%	22.2%	23.4%	23.7%	22.8%	17.4%	16.0%	19.0%	17.8%	20.9%	20.1%	22.9%	21.0%	17.5%	15.6%	18.2%
Dividends Paid	—	$7.9B	$7.6B	$7.3B	$7.5B	$7.4B	$7.0B	$6.6B	$7.0B	$6.5B	$6.5B	$6.6B	$6.8B	$6.1B	$6.0B	$5.4B	$4.5B	$3.9B	$3.3B	$2.6B	$2.0B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NVS Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$5.9B	$3.7B	$2.3B	$6.6B	$6.7B	$3.6B	$4.2B	$6.3B	$4.9B
Capital Expenditures (CapEx)	$758M	$807M	$611M	$831M	$558M	$1.5B	$1.1B	$799M	$728M
Free Cash Flow (FCF)	$5.1B	$2.9B	$1.6B	$5.7B	$6.1B	$2.2B	$3.1B	$5.5B	$4.1B
FCF Margin %	34.3%	21.2%	12.3%	40.0%	41.2%	15.8%	22.6%	41.7%	32.2%
Dividends Paid	—	$6.2B	$10M	$30M	$2.5B	$5.3B	$7.6B	—	$2.4B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NVS Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$122.0B	$115.6B	$102.2B	$99.9B	$117.5B	$131.8B	$132.2B	$118.4B	$145.6B	$133.1B	$130.1B	$131.6B	$125.4B	$126.3B	$124.2B	$117.5B	$123.3B	$95.5B	$78.3B	$75.5B	$68.0B
Cash & Cash Equivalents	$7.6B	$11.4B	$11.5B	$13.4B	$7.5B	$12.4B	$9.7B	$11.1B	$13.3B	$8.9B	$7.0B	$4.7B	$13.0B	$6.7B	$5.6B	$3.7B	$5.3B	$2.9B	$2.0B	$5.4B	$3.8B
Total Liabilities	$80.1B	$69.0B	$58.1B	$53.2B	$58.0B	$64.0B	$75.5B	$62.9B	$66.9B	$58.9B	$55.2B	$54.4B	$54.5B	$51.8B	$55.0B	$51.6B	$53.5B	$38.0B	$27.9B	$26.1B	$26.7B
Total Debt (Short + Long-Term)	$49.0B	$33.7B	$29.7B	$24.8B	$26.4B	$29.4B	$36.1B	$27.4B	$32.1B	$28.4B	$26.0B	$24.2B	$20.4B	$17.9B	$19.7B	$20.2B	$22.9B	$13.9B	$7.0B	$5.6B	$7.2B
Total Shareholders' Equity	$41.5B	$46.1B	$44.0B	$46.7B	$59.3B	$67.7B	$56.6B	$55.5B	$78.6B	$74.2B	$74.8B	$77.0B	$70.8B	$74.3B	$69.1B	$65.8B	$63.2B	$57.4B	$50.3B	$49.2B	$41.1B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NVS viewer.

NVS Metric Deep Dives

Other Companies in DRUG MANUFACTURERS - GENERAL

AZN · AstraZeneca PLC — $258 billion
NVO · Novo Nordisk A/S — $191 billion
SNY · Sanofi ADR — $102 billion
GSK · GlaxoSmithKline PLC ADR — $101 billion
GRFS · Grifols SA ADR — $5 billion
OGN · Organon & Co — $4 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← NVRI All “N” companies NVST →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.